Insider trades by month
US insider trades, January 2025
The 8,151 open-market buys and sales by US company CEOs, executives and directors filed in January 2025.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Viking Global Investors Lp10% Owner | BridgeBio PharmaBBIO | Open-market sale | 25/01/31 | 25/01/31 | 3,065,616 sh | $34.90 | $106,989,998.4 | −12.2% |
CEO and Chairman | Tempus AITEM | Open-market sale | 25/01/29–25/01/31 | 25/01/31 | 238,800 sh6 trades | $55.61avg. | $13,278,632.36 | −4.1% |
Director | HagertyHGTY | Open-market sale10b5-1 plan | 25/01/29–25/01/31 | 25/01/31 | 10,932 sh3 trades | $9.72avg. | $106,259.04 | −0.3% |
Ole Andreas Halvorsen10% Owner | BridgeBio PharmaBBIO | Open-market sale | 25/01/31 | 25/01/31 | 3,065,616 sh | $34.90 | $106,989,998.4 | −12.2% |
Teledyne TechnologiesTDY | Open-market sale | 25/01/31 | 25/01/31 | 5,768 sh2 trades | $518.22avg. | $2,989,080.94 | −3.8% | |
Gary L. HinkleDirector | Burke & Herbert Financial ServicesBHRB | Open-market buy | 25/01/31 | 25/01/31 | 1,000 sh | $64.48 | $64,480 | +0.4% |
AlphabetGOOGL | Open-market sale10b5-1 plan | 25/01/31 | 25/01/31 | 26,000 sh2 trades | $205.00avg. | $5,330,000 | No record | |
Michael RaabPresident & CEO | ArdelyxARDX | Open-market sale10b5-1 plan | 25/01/31 | 25/01/31 | 41,666 sh | $5.36 | $223,329.76 | −3.6% |
Prokopios Akis TsirigakisCEO, President and COB | Stellar V CapitalSVCC | Open-market buy | 25/01/31 | 25/01/31 | 365,000 sh | In footnote | No stated value | No record |
George SyllantavosCo-CEO and CFO | Stellar V CapitalSVCC | Open-market buy | 25/01/31 | 25/01/31 | 365,000 sh | In footnote | No stated value | No record |
Weave CommunicationsWEAV | Open-market sale10b5-1 plan | 25/01/29–25/01/31 | 25/01/31 | 204,491 sh6 trades | $16.51avg. | $3,376,582.53 | −52.0% | |
Triller GroupILLR | Open-market sale | 25/01/29–25/01/31 | 25/01/31 | 156,659 sh3 trades | $1.95avg. | $305,418.23 | −21.8% | |
10% Owner | Sky Harbour GroupSKYH | Open-market sale | 25/01/29–25/01/31 | 25/01/31 | 24,899 sh3 trades | $11.16avg. | $277,874.21 | −0.2% |
Oncotelic TherapeuticsOTLC | Open-market buy | 25/01/29–25/01/31 | 25/01/31 | 346,844 sh3 trades | $0.03avg. | $10,405.32 | +0.4% | |
CodexisCDXS | Open-market buy | 25/01/30–25/01/31 | 25/01/31 | 65,000 sh2 trades | $4.35avg. | $282,850 | +0.8% | |
ThredUpTDUP | Open-market sale10b5-1 plan | 25/01/29–25/01/31 | 25/01/31 | 251,097 sh9 trades | $2.21avg. | $555,599.17 | −100.0% | |
David C. Ott10% Owner | BridgeBio PharmaBBIO | Open-market sale | 25/01/31 | 25/01/31 | 3,065,616 sh | $34.90 | $106,989,998.4 | −12.2% |
BridgeBio PharmaBBIO | Open-market sale | 25/01/31 | 25/01/31 | 3,065,616 sh | $34.90 | $106,989,998.4 | −12.2% | |
Viking Global Opportunities GP10% Owner | BridgeBio PharmaBBIO | Open-market sale | 25/01/31 | 25/01/31 | 3,065,616 sh | $34.90 | $106,989,998.4 | −12.2% |
BridgeBio PharmaBBIO | Open-market sale | 25/01/31 | 25/01/31 | 3,065,616 sh | $34.90 | $106,989,998.4 | −12.2% |
Other months
- September 20262,606
- June 202620,298
- May 202614,504
- April 20269,432
- March 202614,721
- February 202610,638
- January 20267,844
- December 202512,093
- November 202511,751
- October 202513,072
- September 202513,090
- August 202514,381
- July 20258,748
- June 202511,426
- May 202511,415
- April 20256,792
- March 202512,399
- February 202510,686
- January 20258,151
- December 202416,069
- November 202416,983
- October 20248,518
- September 202410,511
- August 202414,013
- July 202410,847
- June 202412,704
- May 202412,649
- April 20248,608
- March 202417,622
- February 202413,916
- January 20249,748
- December 202314,239
- November 202312,685
- October 20236,365
- September 20239,845
- August 202312,892
- July 20237,232
- June 202311,204
- May 202313,009
- April 20235,870
- March 202313,084
- February 202311,300
- January 20238,626